1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
197.85%
Cash & equivalents changing by 197.85% while Drug Manufacturers - Specialty & Generic maintains stable levels. Benjamin Graham would examine if this divergence is justified.
-31.94%
Short-term investments yoy growth below half the Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
42.05%
Cash + STI yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
-52.39%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
43.08%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
98.43%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
35.43%
Current assets growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a potential liquidity edge if well allocated.
42.58%
PP&E growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
-1.91%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-10.96%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-7.27%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
10.23%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
117413800.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
2.90%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
26.21%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.61%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
30.23%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.22%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
231.59%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-3.97%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
128.60%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-10.84%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
No Data
No Data available this quarter, please select a different quarter.
118.75%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 1.32%. Jim Chanos suspects potential working capital strain.
-2.97%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects hidden or rapidly growing miscellaneous liabilities.
24.31%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.12%. Jim Chanos suspects an alarming rise in overall leverage.
29.74%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
56.09%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees stronger retained profit growth vs. peers.
40.50%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
30.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
31.06%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.13%. Joel Greenblatt sees stronger equity growth vs. peers.
30.23%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.99%. Joel Greenblatt sees more aggressive expansions than peers.
-11.20%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-3.01%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-1451.60%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
